MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Chiusa

2.21 3.76

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.11

Massimo

2.24

Metriche Chiave

By Trading Economics

Entrata

53M

-46M

Vendite

-8.8M

56M

EPS

-0.02

Margine di Profitto

-82.429

Dipendenti

570

EBITDA

127M

-21M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+157.41% upside

Dividendi

By Dow Jones

Utili prossimi

7 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-66M

600M

Apertura precedente

-1.55

Chiusura precedente

2.21

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 apr 2025, 23:55 UTC

Azioni calde

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr 2025, 22:50 UTC

I principali Market Mover

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr 2025, 21:08 UTC

Utili

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr 2025, 21:00 UTC

Utili

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr 2025, 23:56 UTC

Discorsi di Mercato

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr 2025, 23:44 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 apr 2025, 23:44 UTC

Discorsi di Mercato

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr 2025, 23:44 UTC

Notizie principali

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr 2025, 23:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 apr 2025, 23:12 UTC

Discorsi di Mercato

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr 2025, 23:10 UTC

Discorsi di Mercato

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr 2025, 23:09 UTC

Discorsi di Mercato

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr 2025, 23:09 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:57 UTC

Discorsi di Mercato

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr 2025, 22:56 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:56 UTC

Discorsi di Mercato

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr 2025, 22:43 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr 2025, 22:12 UTC

Discorsi di Mercato

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr 2025, 21:48 UTC

Notizie principali

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr 2025, 21:41 UTC

Discorsi di Mercato

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr 2025, 21:04 UTC

Notizie principali

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr 2025, 21:03 UTC

Discorsi di Mercato

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr 2025, 20:53 UTC

Utili

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr 2025, 20:52 UTC

Utili

Kaiser Aluminum Changes Inventory Acctg Methodology

Confronto tra pari

Modifica del prezzo

Maravai LifeSciences Holdings Inc (Class A) Previsione

Obiettivo di Prezzo

By TipRanks

157.41% in crescita

Previsioni per 12 mesi

Media 5.56 USD  157.41%

Alto 10 USD

Basso 2.5 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Maravai LifeSciences Holdings Inc (Class A) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

6

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.19 / 2.25Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.